Author of

• 17629

  +

  P2.03b - Poster Session with Presenters Present (ID 465)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 17678

    +

    P2.03b-049 - Molecular & Clinical Status of Current Biomarkers: EGFR, ALK, ROS, MET of Lung Cancer in North Indian Patients (ID 5132)

    14:30 - 14:30  |  Author(s): A. Mehta
    • Abstract

    Background:
    Lung cancer treatment has taken a paradigm shift with advent of molecular therapy. This study evaluates lung adenocarcinoma cases for molecular markers EGFR, ALK, ROS-1 and MET testing.
    
    Methods:
    A total of 4485 cases of lung carcinomas were enrolled from the period of October 2010 to June 2016 in a North Indian tertiary Cancer Centre. Amongst these 815 cases after workup were found to be stage IV adenocarcinoma. Molecular mutation analysis was done for EGFR, ALK, ROS1 and C-MET amplification in 778, 522, 51 and 50 cases respectively. EGFR mutation testing was done using Qiagen Therascreen EGFR kit and Sanger sequencing, ALK testing was done using ALK IHC (clone anti-ALK D5F3) ,ROS1 gene rearrangement and MET gene amplification using Zytolight DNA FISH probes. The incidence of these biomarkers and its association with the age, sex, smoking history, histological subtype, site of biopsy, treatment history and survival outcome would be analyzed.
    
    Results:
    Late breaking. Will complete information later
    
    Conclusion:
    Late breaking abstract. Will be completed later